These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9561093)

  • 1. Use of intravenous Optison contrast echocardiography reduces downstream resource use and enhances cost savings.
    Shaw LJ; Dittrich HC
    Acad Radiol; 1998 Apr; 5 Suppl 1():S250-1; discussion S252-3. PubMed ID: 9561093
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of contrast for image enhancement during stress echocardiography is cost-effective and reduces additional diagnostic testing.
    Thanigaraj S; Nease RF; Schechtman KB; Wade RL; Loslo S; Pérez JE
    Am J Cardiol; 2001 Jun; 87(12):1430-2. PubMed ID: 11397374
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and time-efficiency of a "sonographer-driven" contrast echocardiography protocol in a high-volume echocardiography laboratory.
    Castello R; Bella JN; Rovner A; Swan J; Smith J; Shaw L
    Am Heart J; 2003 Mar; 145(3):535-41. PubMed ID: 12660679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reimbursement for new diagnostic imaging technologies: process, progress, and problems.
    Pearlman AS
    Am J Cardiol; 2002 Nov; 90(10A):17J-20J. PubMed ID: 12450586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac imaging using Optison.
    Clark LN; Dittrich HC
    Am J Cardiol; 2000 Aug; 86(4A):14G-18G. PubMed ID: 10997346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of contrast echocardiography on diagnostic algorithms: pharmacoeconomic implications.
    Shaw LJ
    Clin Cardiol; 1997 Oct; 20(10 Suppl 1):I39-48. PubMed ID: 9383601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial.
    Cohen JL; Cheirif J; Segar DS; Gillam LD; Gottdiener JS; Hausnerova E; Bruns DE
    J Am Coll Cardiol; 1998 Sep; 32(3):746-52. PubMed ID: 9741522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Optison on pulmonary artery systolic pressure and pulmonary vascular resistance.
    Main ML; Grayburn PA; Lang RM; Goldman JH; Gibson CM; Sherwin P; DeMaria AN
    Am J Cardiol; 2013 Nov; 112(10):1657-61. PubMed ID: 24041914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of harmonic imaging for left ventricular opacification and endocardial border delineation by optison.
    Al-Mansour HA; Mulvagh SL; Pumper GM; Klarich KW; Foley DA
    Am J Cardiol; 2000 Mar; 85(6):795-9, A10. PubMed ID: 12000067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of transducer frequency and output power on the ultrasonographic contrast produced by Optison using fundamental and harmonic imaging techniques.
    Wible JH; Wojdyla JK; Hughes MS; Brandenburger GH
    J Ultrasound Med; 1999 Nov; 18(11):753-62. PubMed ID: 10547107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of intravenous contrast imaging in pediatric echocardiography.
    McMahon CJ; Ayres NA; Bezold LI; Lewin MB; Alonzo M; Altman CA; Kovalchin JP; Eidem BW; Pignatelli RH
    Pediatr Cardiol; 2005; 26(4):413-7. PubMed ID: 16374692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of cardiopulmonary bypass and inspired oxygen concentration on left ventricular contrast opacification with optison, a second-generation ultrasound contrast agent.
    Dupont FW; Drum M; Fisher AM; Aronson S
    J Cardiothorac Vasc Anesth; 2002 Apr; 16(2):170-4. PubMed ID: 11957165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an intravenous contrast agent (Optison) to enhance echocardiography: efficacy and cost implications. Optison Multicenter Study Group.
    Shaw LJ; Gillam L; Feinstein S; Dent J; Plotnick G
    Am J Manag Care; 1998 Sep; 4 Spec No():SP169-76. PubMed ID: 10185992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applying principles of pharmacoeconomic evaluation to perflenapent emulsion, a new echocardiographic contrast agent for use in cardiac function testing.
    Wellman G; Sherrin T
    Clin Ther; 1997; 19(4):837-46. PubMed ID: 9377626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of inhaled gases on the ultrasound contrast produced by microspheres containing air or perfluoropropane in anesthetized dogs.
    Wible J; Wojdyla J; Bugaj J; Brandenburger G
    Invest Radiol; 1998 Dec; 33(12):871-9. PubMed ID: 9851821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of coronary pseudoaneurysm by Optison.
    Naqvi TZ; Lepor NE
    J Am Soc Echocardiogr; 2003 Mar; 16(3):289-92. PubMed ID: 12618739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optison (FS069) disrupts the blood-brain barrier in rats.
    Mychaskiw G; Badr AE; Tibbs R; Clower BR; Zhang JH
    Anesth Analg; 2000 Oct; 91(4):798-803. PubMed ID: 11004029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous myocardial contrast echocardiography predicts recovery of dysynergic myocardium early after acute myocardial infarction.
    Swinburn JM; Lahiri A; Senior R
    J Am Coll Cardiol; 2001 Jul; 38(1):19-25. PubMed ID: 11451273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An observational study of the occurrence of serious adverse reactions among patients who receive optison in routine medical practice.
    Wei K; Shah S; Jaber WA; DeMaria A
    J Am Soc Echocardiogr; 2014 Sep; 27(9):1006-10. PubMed ID: 24930121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of myocardial, hepatic, and renal perfusion in a variety of clinical conditions using an intravenous ultrasound contrast agent (Optison) and second harmonic imaging.
    Hancock J; Dittrich H; Jewitt DE; Monaghan MJ
    Heart; 1999 Jun; 81(6):636-41. PubMed ID: 10336924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.